Back to Search Start Over

Identification of RUNX1 as a Mediator of Aberrant Retinal Angiogenesis.

Authors :
Lam JD
Oh DJ
Wong LL
Amarnani D
Park-Windhol C
Sanchez AV
Cardona-Velez J
McGuone D
Stemmer-Rachamimov AO
Eliott D
Bielenberg DR
van Zyl T
Shen L
Gai X
D'Amore PA
Kim LA
Arboleda-Velasquez JF
Source :
Diabetes [Diabetes] 2017 Jul; Vol. 66 (7), pp. 1950-1956. Date of Electronic Publication: 2017 Apr 11.
Publication Year :
2017

Abstract

Proliferative diabetic retinopathy (PDR) is a common cause of blindness in the developed world's working adult population and affects those with type 1 and type 2 diabetes. We identified Runt-related transcription factor 1 (RUNX1) as a gene upregulated in CD31 <superscript>+</superscript> vascular endothelial cells obtained from human PDR fibrovascular membranes (FVMs) via transcriptomic analysis. In vitro studies using human retinal microvascular endothelial cells (HRMECs) showed increased RUNX1 RNA and protein expression in response to high glucose, whereas RUNX1 inhibition reduced HRMEC migration, proliferation, and tube formation. Immunohistochemical staining for RUNX1 showed reactivity in vessels of patient-derived FVMs and angiogenic tufts in the retina of mice with oxygen-induced retinopathy, suggesting that RUNX1 upregulation is a hallmark of aberrant retinal angiogenesis. Inhibition of RUNX1 activity with the Ro5-3335 small molecule resulted in a significant reduction of neovascular tufts in oxygen-induced retinopathy, supporting the feasibility of targeting RUNX1 in aberrant retinal angiogenesis.<br /> (© 2017 by the American Diabetes Association.)

Details

Language :
English
ISSN :
1939-327X
Volume :
66
Issue :
7
Database :
MEDLINE
Journal :
Diabetes
Publication Type :
Academic Journal
Accession number :
28400392
Full Text :
https://doi.org/10.2337/db16-1035